HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kostakoglu, L. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Kostakoglu, L. Articles by Larson, S. M.

Validation of Gallium-67-Citrate Single-Photon Emission Computed Tomography in Biopsy-Confirmed Residual Hodgkin's Disease in the Mediastinum

Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For reprints contact: Lale Kostakoglu, MD, 245 East 63rd St. #23A, New York, NY 10021.

ABSTRACT

In a retrospective study of a series of 30 adult patients during restaging of Hodgkin's disease after therapy, computed tomography (CT) and biopsy results were correlated with ⁶⁷Ga SPECT in order to determine the value of SPECT imaging in monitoring recurrent mediastinal Hodgkin's disease. SPECT had an overall accuracy of 93% (28/30) and correctly identified active disease in 24 of 25, 96% of histopathologically proven recurrent Hodgkin's disease. Thus in this post-therapy setting, we have confirmed the high sensitivity of ⁶⁷GA SPECT scans in patients selected for biopsy. Gallium-67 may prove particularly useful in detecting residual disease activity in patients in whom biopsy was positive but the interpretations of the CT scans were uncertain in regard to presence of tumors [8/30 (27%)]. In this group of patients, we found SPECT particularly helpful. A larger prospective series is underway to assess this possibility.

This article has been cited by other articles:

				S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48. [Abstract] [Full Text] [PDF]

				M. R. Weihrauch, D. Re, K. Scheidhauer, S. Ansen, M. Dietlein, S. Bischoff, H. Bohlen, J. Wolf, H. Schicha, V. Diehl, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease Blood, November 15, 2001; 98(10): 2930 - 2934. [Abstract] [Full Text] [PDF]

				G. Jerusalem, Y. Beguin, M.F. Fassotte, F. Najjar, P. Paulus, P. Rigo, and G. Fillet Whole-Body Positron Emission Tomography Using 18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin's Disease and Non-Hodgkin's Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging Blood, July 15, 1999; 94(2): 429 - 433. [Abstract] [Full Text] [PDF]

				D. Front, R. Bar-Shalom, M. Mor, N. Haim, R. Epelbaum, A. Frenkel, D. Gaitini, G. M. Kolodny, and O. Israel Hodgkin Disease: Prediction of Outcome with 67Ga Scintigraphy after One Cycle of Chemotherapy Radiology, February 1, 1999; 210(2): 487 - 491. [Abstract] [Full Text]